Effect of Selegiline Administration on the Urinary Excretion of Dopamine-Derived Tetrahydroisoquinoline Alkaloids in Parkinson’s Disease Patients
It has long been suggested that, in humans, the biosynthesis of salsolinol (Sal), a dopamine (DA)-derived isoquinoline alkaloid, might occur by condensation of DA with acetaldehyde or with pyruvic acid followed by oxidative decarboxylation and reduction (Figure 1). Sal possesses an asymmetric center at C-1 and exists as R and S enantiomers. There is supportive evidence that, at least in healthy subjects under physiological conditions, Sal biosynthesis should result from the condensation of DA with pyruvic acid: 1) 1-carboxysalsolinol and 1,2-dehydrosalsolinol (DSal) have been detected in human brain and urine together with Sal (Sjöquist and Ljungquist, 1985; Ung-Chhun et al., 1985; Dostert et al., 1990a); and 2) the presence of only the R enantiomer of Sal in urine of healthy subjects (Dostert et al., 1991) would not be consistent with this compound arising from the non-enzymic condensation of DA with acetaldehyde.
KeywordsPyruvic Acid Sodium Metabisulfite Semicarbazide Hydrochloride Daily Urinary Excretion Platelet Monoamine Oxidase
Unable to display preview. Download preview PDF.
- Dordain, G., Dostert, P., Strolin Benedetti, M., and Rovei, V., 1984, Tetrahydroisoquinoline derivatives and parkinsonism, in: “Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors,” Tipton, K.F., Dostert, P. and Benedetti, M. Strolin, eds., Academic Press, London.Google Scholar
- Dostert, P., Strolin Benedetti, M., Bellotti, V., Dordain, G., Vernay, D., and Deffond, D., 1990b, Urinary excretion of salsolinol enantiomers and 1,2-dehydrosalsolinol in patients with degenerative dementia, in: “Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry, and Clinics (Key Topics in Brain Research),” Maurer, K., Riederer, P. and Beckmann, H., eds., Springer-Verlag, Germany.Google Scholar
- Dostert, P., Strolin Benedetti, M., Della Vedova, F., Allievi, C., La Croix, R., Dordain, G., Vemay, D., and Durif, F., 1993, Dopamine-derived tetrahydroisoquinolines and Parkinson’s disease, in: “Advances in Neurology,” Narahayashi, H., Nagatsu, T., Yanagisawa, N. and Mizuno, Y., eds., Raven Press Ltd., New York.Google Scholar
- Niwa, T., Takeda, N., Yoshizumi, H., Tatematsu, A., Yoshida, M., Dostert, P., Naoi, M., and Nagatsu, T., 1991, Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline,novel endogenous amines, in parkinsonian and normal human brains, Biochem. Biophys. Res. Commun. 177: 603.PubMedCrossRefGoogle Scholar
- Thornton, C., Doré, C.J. Elsworth, J.D., Herbert, M., and Stern, G.M., 1980, The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man, Psychopharmacology 70: 163.Google Scholar
- Ung-Chhun, N., Cheng, B.Y., Pronger, D.A., Serrano, P., Chavez, B., Fernandez Perrez, R., Morales, J., and Collins, M.A., 1985, Alkaloid adducts in human brain: coexistence of 1-carboxylated and noncarboxylated isoquinolines and ß-carbolines in alcoholics and nonalcoholics, Prog. Clin. Biol. Res. Gggg 183: 125.Google Scholar